Axxium Life, Inc., developing peptide-based Active Immunotherapy Medicine (AIM), encountered a critical quality control issue where a manufacturing change caused a significant drop in drug potency that went undetected by conventional analytical methods. To solve this, Axxium utlilized RedShift Bio's AuroraTX instrument with its (MMS) technology to analyze the peptide's higher-order structure (HOS). The MMS analysis was able to correlate differences in the nature and kinetics of peptide aggregation with the batches' reduced potency, providing the missing link. This breakthrough established a measurable characteristic that directly impacts product quality and stability. Axxium now plans to leverage this MMS method to expedite process development and improve API characterization. Importantly, this technology may eventually serve as a formal quality control metric for future batch release. This work validates MMS as a promising tool for ensuring the quality of Axxium's peptide drug products.